Traders Buy Shares of Thermo Fisher Scientific (TMO) on Weakness
Investors purchased shares of Thermo Fisher Scientific Inc. (NYSE:TMO) on weakness during trading on Friday. $144.99 million flowed into the stock on the tick-up and $85.25 million flowed out of the stock on the tick-down, for a money net flow of $59.74 million into the stock. Of all companies tracked, Thermo Fisher Scientific had the 31st highest net in-flow for the day. Thermo Fisher Scientific traded down ($6.18) for the day and closed at $235.86
A number of equities research analysts have commented on TMO shares. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $271.00 target price for the company in a report on Friday. Morgan Stanley raised their target price on Thermo Fisher Scientific from $254.00 to $260.00 and gave the company an “overweight” rating in a report on Thursday, October 25th. Robert W. Baird raised their target price on Thermo Fisher Scientific from $256.00 to $264.00 and gave the company an “outperform” rating in a report on Thursday, October 25th. Cleveland Research downgraded Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a report on Thursday, October 18th. Finally, Citigroup raised their target price on Thermo Fisher Scientific from $260.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, October 10th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $263.64.
The company has a debt-to-equity ratio of 0.66, a current ratio of 1.84 and a quick ratio of 1.27. The firm has a market cap of $98.18 billion, a P/E ratio of 24.85, a price-to-earnings-growth ratio of 1.77 and a beta of 1.09.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, January 15th. Shareholders of record on Monday, December 17th will be issued a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date is Friday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 7.17%.
Thermo Fisher Scientific declared that its board has initiated a stock repurchase program on Friday, September 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2.1% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s leadership believes its stock is undervalued.
In other news, Director Tyler Jacks sold 1,100 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, December 4th. The stock was sold at an average price of $251.98, for a total transaction of $277,178.00. Following the completion of the transaction, the director now owns 5,879 shares of the company’s stock, valued at approximately $1,481,390.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Gregory J. Herrema sold 17,235 shares of Thermo Fisher Scientific stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $247.00, for a total value of $4,257,045.00. Following the transaction, the insider now directly owns 26,446 shares of the company’s stock, valued at approximately $6,532,162. The disclosure for this sale can be found here. Insiders have sold a total of 148,627 shares of company stock valued at $36,744,510 in the last ninety days. Corporate insiders own 0.49% of the company’s stock.
Several large investors have recently added to or reduced their stakes in TMO. K.J. Harrison & Partners Inc acquired a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $3,661,000. First Trust Advisors LP raised its stake in Thermo Fisher Scientific by 92.5% in the 3rd quarter. First Trust Advisors LP now owns 303,090 shares of the medical research company’s stock valued at $73,978,000 after purchasing an additional 145,619 shares during the last quarter. Oakworth Capital Inc. raised its stake in Thermo Fisher Scientific by 30.0% in the 3rd quarter. Oakworth Capital Inc. now owns 1,476 shares of the medical research company’s stock valued at $360,000 after purchasing an additional 341 shares during the last quarter. Swiss National Bank raised its stake in Thermo Fisher Scientific by 3.2% in the 2nd quarter. Swiss National Bank now owns 1,328,332 shares of the medical research company’s stock valued at $275,151,000 after purchasing an additional 41,800 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV raised its stake in Thermo Fisher Scientific by 6,260.5% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 13,039 shares of the medical research company’s stock valued at $2,701,000 after purchasing an additional 12,834 shares during the last quarter. 86.98% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/traders-buy-shares-of-thermo-fisher-scientific-tmo-on-weakness/2668740.html.
Thermo Fisher Scientific Company Profile (NYSE:TMO)
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: What Are Treasury Bonds?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.